OBIGEN Pharma&rsquo;s OBI-858 is approved by INTELLECTUAL PROPERTY CORPORATION OF MALAYSIA (MyIPO) on 2nd October 2024. No.&nbsp;MY-205101-A with the title of invention as&nbsp;&ldquo;BOTULINUM TOXIN TYPE A COMPLEX, AND FORMULATION THEREOF AND USAGE METHOD THEREFOR&rdquo;, certificate of grant of a patent as the below.
<img src="/uploads/%E6%8A%95%E8%B3%87%E4%BA%BA%E5%B0%88%E5%8D%80_%E9%87%8D%E5%A4%A7%E5%85%AC%E5%91%8A/%E9%A6%AC%E4%BE%86%E8%A5%BF%E4%BA%9E_OBI-858-PI2021006978-Certificate%20of%20Grant%20%20Patent%20Documents.jpg" alt="馬來西亞_OBI-858-PI2021006978-Certificate of Grant Patent Documents.jpg" width="2480" height="3506" />

OBI-858 Approved by INTELLECTUAL PROPERTY CORPORATION OF MALAYSIA (MyIPO), No. MY-205101-A